Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024
Publication date
2024-03-07
Authors
Huiberts, Anne J
Hoeve, Christina E
de Gier, Brechje
Cremer, Jeroen
van der Veer, Bas
de Melker, Hester E
van de Wijgert, Janneke H H M
van den Hof, Susan
Eggink, Dirk
Knol, Mirjam J
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
No license information available
Abstract
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).
Keywords
Journal Article
Citation
Huiberts, A J, Hoeve, C E, de Gier, B, Cremer, J, van der Veer, B, de Melker, H E, van de Wijgert, J H, van den Hof, S, Eggink, D & Knol, M J 2024, 'Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024', Eurosurveillance, vol. 29, no. 10, e2400109. https://doi.org/10.2807/1560-7917.ES.2024.29.10.2400109